A feasibility analysis of the ArcBlate MR-guided high-intensity focused ultrasound system for the ablation of uterine fibroids
| Autor: | Chin‑Jung Wang, Yi-Ting Huang, Kai‑Yun Wu, Cindy Hsuan Weng, Gigin Lin, Yu‑Ying Su, Kit‑Sum Mak, Yu-Shan Lin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Uterine fibroids Urology medicine.medical_treatment Pelvis 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Quality of life medicine Humans Uterine fibroid Radiology Nuclear Medicine and imaging Adenomyosis Adverse effect 030219 obstetrics & reproductive medicine Leiomyoma Radiological and Ultrasound Technology medicine.diagnostic_test business.industry Magnetic resonance-guided high-intensity focused ultrasound Gastroenterology Correction Magnetic resonance imaging medicine.disease Ablation Magnetic Resonance Imaging female genital diseases and pregnancy complications High-intensity focused ultrasound Treatment Outcome Uterine Neoplasms Quality of Life Feasibility Studies Female Radiology business |
| Zdroj: | Abdom Radiol (NY) Abdominal Radiology (New York) |
| ISSN: | 2366-0058 2366-004X |
| Popis: | Purpose Uterine fibroids are benign gynecologic tumors and commonly occur in women by the age of 50. Women with symptomatic uterine fibroids generally receive surgical intervention, while they do not favor the invasive therapies. To evaluate the feasibility and safety of a novel magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) modality, ArcBlate, in the treatment of uterine fibroids. Methods Nine patients with uterine fibroids and one patient with adenomyosis were treated with ArcBlate MRgHIFU. Tumor size and quality of life were evaluated postoperatively at 1 and 3 months by magnetic resonance imaging (MRI) and the 36-Item Short Form Survey (SF-36), respectively. Results All patients completed the ArcBlate MRgHIFU procedure and there were no treatment-related adverse effects either during the procedure or during the 3 months of follow-up. Despite limiting the ablation volume to under 50% of the treated fibroid volume as a safety precaution, tumor volumes were markedly reduced in four patients by 15.78–58.87% at 3-month post-treatment. Moreover, SF-36 scale scores had improved at 3 months from baseline by 2–8 points in six patients, indicating relief of symptoms and improved quality of life. Conclusion This study evidence demonstrates the safety and feasibility of ArcBlate MRgHIFU and suggests its potential for treating uterine fibroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink